Hypothesis

Systemic sclerosis-associated interstitial lung disease (SSc-ILD) progression is currently detected by serial HRCT and pulmonary function tests (FVC decline ≥10%), but these measures lag behind actual parenchymal injury. We hypothesize that circulating cell-free DNA (cfDNA) fragments bearing alveolar type II (AT2) cell-specific methylation patterns — detectable via targeted bisulfite sequencing of SFTPC, SFTPB, and NKX2-1 promoter regions — will identify active AT2 apoptosis and predict HRCT-confirmed ILD progression 6–12 months before conventional radiographic or spirometric deterioration.

Rationale

AT2 cells are the primary regenerative progenitors of the alveolar epithelium. In SSc-ILD, fibrotic remodeling is preceded by AT2 injury and apoptosis, releasing cfDNA with tissue-specific methylation marks into circulation. This principle has been validated in type 1 diabetes (beta-cell cfDNA) and hepatocellular injury (hepatocyte cfDNA), but has not been applied to pulmonary fibrosis in autoimmune disease. The methylation status of surfactant protein gene promoters (SFTPC, SFTPB) and the lung-lineage transcription factor NKX2-1 are highly specific to AT2 cells, providing a natural deconvolution signal.

Testable Predictions

1. Primary: SSc patients who progress on HRCT (fibrosis extent increase ≥5% by quantitative CT) within 12 months will show significantly elevated AT2-derived cfDNA fractions at baseline compared to non-progressors (AUC ≥0.80, p<0.01 after Bonferroni correction).
2. Secondary: The AT2-cfDNA signal will correlate with KL-6 and SP-D serum levels (Spearman ρ ≥0.5) but provide superior prognostic discrimination (net reclassification improvement >0.15 over KL-6 alone).
3. Temporal: In a longitudinal sub-cohort sampled quarterly, rising AT2-cfDNA trajectories (slope >2 SD above stable patients) will precede FVC decline ≥5% by a median of 6–9 months.
4. Falsification: If AT2-cfDNA fractions do not differ between progressors and non-progressors at any time point (p>0.20), the hypothesis is refuted.

Proposed Design

Prospective cohort, n=120 SSc patients (60 with baseline ILD, 60 without), followed 18 months with quarterly cfDNA sampling, serial HRCT at 0/12/18 months, and monthly PFTs. Targeted bisulfite sequencing panel covering 15 CpG sites across SFTPC/SFTPB/NKX2-1. Primary analysis: logistic regression with LASSO regularization; sensitivity analysis via Bayesian hierarchical model with informative priors from beta-cell cfDNA literature.

Limitations

• cfDNA half-life (~1–2 hours) means sampling timing relative to active injury episodes may affect sensitivity
• Immunosuppressive therapy (mycophenolate, nintedanib) may attenuate AT2 apoptosis signal
• Quantitative HRCT scoring has inter-reader variability (~5%) near the progression threshold
• Single-center design limits generalizability; multi-site validation needed
• Cost of targeted bisulfite sequencing may limit clinical scalability without panel miniaturization

Clinical Significance

Early identification of SSc-ILD progressors would enable timely initiation or escalation of antifibrotic therapy (nintedanib) and immunosuppression before irreversible architectural distortion occurs. A blood-based biomarker would reduce radiation exposure from serial HRCTs and enable more frequent monitoring. Integration into existing SSc clinical scoring systems (e.g., modified Rodnan skin score trajectories) could yield a composite digital-molecular disease activity index.

LES AI • DeSci Rheumatology